Nongastric marginal zone B‐cell lymphoma: Analysis of 247 cases

Abstract

Nongastric marginal zone B-cell lymphoma (NG-MZL) is a relatively uncommon indolent lymphoma. From 1990 to 2005, a total of 247 patients with histologically confirmed NG-MZL were analyzed. Ann Arbor stage I/II disease was present in 78% (167 out of 215). One hundred eighty-six patients out of two hundred eight were categorized into the low/low-intermediate risk group (89%) according to International Prognostic Index (IPI). Eighty percent (172/ 215) were in low risk group according to Follicular Lymphoma International Prognostic Index (FLIPI). Complete and partial remissions (CR and PR) were achieved in 140 (92.7%) and 8 (5.3%) of the 151 stage I/II patients. Especially, radiation containing treatment achieved 96% CR rate (108 out of 113). In 38 patients with stage III/IV, CR and PR were achieved in 17 (44.7%) and 11 (26.3%), respectively. The estimated five-year overall survival (OS) and progression-free survival (PFS) were 93.8% and 70.1%, respectively. Although anthracyclinecontaining regimen could achieve higher CR rate, it did not improve PFS. Stage III/IV, low hemoglobin, poor performance status, high/high-intermediate IPI, poor risk FLIPI, and nodal MZL were poor prognostic factors for PFS. NG-MZL is an indolent disease. FLIPI has strong power to predict the prognosis of NG-MZL. Am. J. Hematol. 82:446-452, 2007.Wiley-Liss, Inc.

Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial

“…In the retrospective data, advanced MZL was shown to be controlled well with chemother- apy. The response rates of 1st line and 2nd line chemotherapy in cases of advanced MZL were 75% and 63%, respectively [1]. The reason for our disappointing results remains unclear.…”

“…Marginal zone lymphoma (MZL) is a distinct subgroup of non-Hodgkin's lymphoma (NHL), which is typically characterized by an indolent clinical course and long survival [1][2][3][4]. Therapeutic approaches for the treatment of MZL continue to evolve.…”

“…As MZLs tend to remain localized for a long time, MZL responds favorably to local treatments, including surgery and/or local radiation therapy [7,8]. However, MZL manifests as a disseminated disease in one-third of the cases at diagnosis [1,2,4]. Moreover, relapses involving distant sites after local therapy have been previously reported [2,3,9].…”

Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study

“…Advanced-stage MZL accounts for 20-50% of all MZL [1,3,8,12], and MM-MZL accounts for approximately one-third of cases of advanced-stage MZL [1,3,8,9]. In a study in which 158 patients were enrolled, only 18 (11%) evidenced multiple organ localization [1]; 7 (3.5%) exhibited stomach and intestinal tract involvement; and 5 (3%) evidenced GI tract and lung involvement.…”

Primary MALToma of the Prostate.

“…3 Most localized MALToma cases respond well to local therapy, including surgery and radiation therapy. MALToma of the stomach is highly sensitive to radiation therapy.…”